Keywords: glucagon like peptide-1, irritable bowel syndrome, pain, IBS, agonist Introduction Irritable bowel syndrome (IBS) is a prevalent and debilitating gastrointestinal condition characterized by recurrent flare-ups of symptoms such as increased central pain, bloating, diarrhea, and constipation (1, 2)
Extending the dynamic range of GLP-1 quantitation using the Thermo Scientific Stellar MS Peptide-based biomarkers and biotherapeutic agents such as GLP-1 present significant challenges to meet quantitative sensitivity requirements
Aid in the production of antibodies and white blood cells to fight infections
The NAC group showed a significant increase in brain regions associated with Parkinson's compared to the control group, indicating a potential positive effect on the dopaminergic system
Additionally, some regulatory discussion surrounds potential future coverage restrictions under Medicare or Medicaid, driven by cost concerns rather than safety